GM103
AXP000043.1 · Oncolytic virus
- Platform
- adenovirus
- Originator
- GeneMedicine Co.
- Sponsor
- GeneMedicine Co.
Names
| Name | Type | Source |
|---|---|---|
| GM103 | preferred name, code | curator, ncit |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Replication
- conditionally replicating
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C208077
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | Recruiting | Phase 1/2 | 2024-02-20 | 2025-05-30 | 125 | Breast Cancer; Cervical Cancer; Colorectal Cancer; Head and Neck Cancer; Malignant Melanoma; Renal Cell Carcinoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 30703976 | First Report of Geosmithia morbida on English Walnut and its Paradox Rootstock in California. | Plant disease | 2014 | name in abstract: GM103 |
Notes
Korean oncolytic adenovirus; phase I/II NCT06265025, intratumoral, alone and with pembrolizumab. Transgenes and backbone not stated in any source consulted; left empty rather than guessed.
How to cite
GM103 (AXP000043.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000043.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.